;

9.24 EUR

Opening hours: 09:00 - 17:30 (Central European Standard Time: 12/24/2024 5:46:34 PM)
Exchange closed, opens in 15 hours 13 minutes
3.00 EUR (3.00%)
-7.14 EUR (-7.14%)
-17.65 EUR (-17.65%)
15.50 EUR (15.50%)
-35.38 EUR (-35.38%)
-69.60 EUR (-69.60%)
-32.00 EUR (-32.00%)
386.04 EUR (386.04%)

About Grifols SA

Market Capitalization 5.55B

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Headquarters (address)

Avinguda de la Generalitat, 152

Barcelona 08174

Spain

Phone34 935 712 200
Websitehttps://www.grifols.com
Employees23K
SectorHealthcare
IndustryDrug Manufacturers General
TickerGRF
ExchangeMadrid Stock Exchange
CurrencyEUR
52 week range6.36 - 15.92
Market Capitalization5.55B
Dividend yield forward15.72 %
Dividend yield forward Spain (ID:221, base:120) 11.71 %
P/E trailing37.06
P/E forward15.07
Price/Sale3.00
Price/Book1.13
Beta3.00
EPS3.00
EPS Spain (ID:221, base:143) 3.00

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Grifols SA has raised their dividend 15.72 years in a row. This is below the 42121.883100 year average in the 'Drug Manufacturers General' industry

Forward Annual Dividend Yield

Forward Annual Dividend Yield: Grifols SA has raised their dividend 15.72 years in a row. This is below the 42121.883100 year average in the 'Drug Manufacturers General' industry

CleverShares.com|
2024 ©

1.0.9119.29486